New York State Psychiatric Institute/Department of Psychiatry, Columbia University Vagelos College of Physicians & Surgeons, 1051 Riverside Drive, New York, NY, USA.
Columbia University Mailman School of Public Health, New York, NY, USA.
J Gen Intern Med. 2023 Feb;38(2):390-398. doi: 10.1007/s11606-022-07686-z. Epub 2022 Jun 3.
Rising opioid-related death rates have prompted reductions of opioid prescribing, yet limited data exist on population-level associations between opioid prescribing and opioid-related deaths.
To evaluate population-level associations between five opioid prescribing measures and opioid-related deaths.
An ecological panel analysis was performed using linear regression models with year and commuting zone fixed effects.
People ≥10 years aggregated into 886 commuting zones, which are geographic regions collectively comprising the entire USA.
Annual opioid prescriptions were measured with IQVIA Real World Longitudinal Prescription Data including 76.5% (2009) to 90.0% (2017) of US prescriptions. Prescription measures included opioid prescriptions per capita, percent of population with ≥1 opioid prescription, percent with high-dose prescription, percent with long-term prescription, and percent with opioid prescriptions from ≥3 prescribers. Outcomes were age- and sex-standardized associations of change in opioid prescriptions with change in deaths involving any opioids, synthetics other than methadone, heroin but not synthetics or methadone, and prescription opioids, but not other opioids.
Change in total regional opioid-related deaths was positively correlated with change in regional opioid prescriptions per capita (β=.110, p<.001), percent with ≥1 opioid prescription (β=.100, p=.001), and percent with high-dose prescription (β=.081, p<.001). Change in total regional deaths involving prescription opioids was positively correlated with change in all five opioid prescribing measures. Conversely, change in total regional deaths involving synthetic opioids was negatively correlated with change in percent with long-term opioid prescriptions and percent with ≥3 prescribers, but not for persons ≥45 years. Change in total regional deaths in heroin was not associated with change in any prescription measure.
Regional decreases in opioid prescriptions were associated with declines in overdose deaths involving prescription opioids, but were also associated with increases in deaths involving synthetic opioids (primarily fentanyl). Individual-level inferences are limited by the ecological nature of the analysis.
阿片类药物相关死亡率的上升促使阿片类药物的处方量减少,但关于阿片类药物处方与阿片类药物相关死亡之间的人群水平关联的数据有限。
评估五种阿片类药物处方措施与阿片类药物相关死亡之间的人群水平关联。
使用具有年份和通勤区固定效应的线性回归模型进行生态面板分析。
将年龄≥10 岁的人群汇总到 886 个通勤区,这些区域共同构成了整个美国。
使用 IQVIA 真实世界纵向处方数据衡量年度阿片类药物处方,该数据包括 2009 年至 2017 年 76.5%至 90.0%的美国处方。处方措施包括每人口的阿片类药物处方、≥1 个阿片类药物处方的人口比例、高剂量处方比例、长期处方比例以及≥3 名开方医生的阿片类药物处方比例。结果是年龄和性别标准化的阿片类药物处方变化与涉及任何阿片类药物、非美沙酮合成药物、海洛因但不包括合成药物或美沙酮、以及处方阿片类药物的死亡变化之间的关联。
区域内阿片类药物相关死亡的变化与区域内每人口阿片类药物处方的变化(β=0.110,p<.001)、≥1 个阿片类药物处方的人口比例(β=0.100,p=.001)和高剂量处方的比例(β=0.081,p<.001)呈正相关。区域内涉及处方阿片类药物的总死亡变化与所有五种阿片类药物处方措施的变化呈正相关。相反,区域内涉及合成阿片类药物的总死亡变化与长期阿片类药物处方比例和≥3 名开方医生的比例呈负相关,但≥45 岁人群除外。区域内海洛因总死亡与任何处方措施的变化无关。
阿片类药物处方的区域减少与涉及处方阿片类药物的过量死亡下降有关,但也与涉及合成阿片类药物(主要是芬太尼)的死亡增加有关。个体水平的推论受到分析的生态性质的限制。